Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced a 30-minute oral presentation on TG4050, the ...

FS Vector, a leading Washington, D.C.-based strategic consulting firm for companies innovating in financial services, today ...

Full-year results and business updateTransgene Continues Progressto Reshape Early-Stage Cancer Treatmentthrough Individualized Neoantigen ...

Wrap Technologies, Inc. (NASDAQ: WRAP) (“Wrap”), a global leader in Non-Lethal Response (“NLR”) technologies and public ...

New National Forecast Signals Expanding Vector-Borne Disease Risk for Dogs -- with Implications for Human Health and a 94%+ Accurate Early Warning System SALEM, Ore., March 23, 2026 /PRNewswire/ -- ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

Nadofaragene firadenovec-vncg is the only FDA-approved nonreplicating intravesical gene therapy for high-risk BCG-unresponsive NMIBC with CIS ± papillary tumors, administered quarterly via catheter.

Facing budget shortfall, the county government organization that fights pests is asking voters to approve a fee to help it ...

Open-source is nice, but that’s not the interesting part here.

Arm is allowing vendors like Supermicro and Lenovo to deliver rack-based solutions, but the company did highlight what these ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

Los Angeles County’s effort to suppress mosquitoes through sterile-male releases is facing funding uncertainty that could complicate operations, even as public health agencies continue to monitor ...